Our study also revealed that SMYD2 inhibition led to the down-regulation of P-gP, which is an ATP-binding cassette multidrug transporter 47, thus enhancing the chemotherapeutic drug sensitivity in RCC cells. This evidence concerns the gene SMYD2 and renal cell carcinoma.